In contrast, a previous study of upper tract urothelial cancer, reported loss of immunohistochemical MMR protein expression in 30% of the patients with a common Lynch syndrome-associated cancer, including patients with no verified Lynch syndrome-associated pathogenic MMR variant, and it was not possible to extract the numbers from verified Lynch syndrome individuals only (40). The gene discussed is MRC1; the disease is cancer.